Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03976375
Other study ID # 7902-008
Secondary ID MK-7902-008LEAP-
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 26, 2019
Est. completion date September 18, 2024

Study information

Verified date March 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS); and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 422
Est. completion date September 18, 2024
Est. primary completion date August 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has a histologically or cytologically confirmed diagnosis of metastatic squamous or nonsquamous NSCLC (Stage IV: M1a, M1b, M1c). - Has PD on treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. - Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment - Has PD during/after platinum doublet chemotherapy for metastatic disease. - Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations [eg, DEL19 or L858R], and absence of ALK and ROS1 gene rearrangements OR presence of a K-ras mutation). - Has submitted pre-study imaging that confirmed evidence of PD following initiation of an anti-PD-1/PD-L1 inhibitor. - Has at least 1 measurable lesion by computerized tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1, as determined by the local site assessment. - Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample (defined as: from initial diagnosis of NSCLC and prior to receiving immunotherapy [antiPD-1/PD-L1], from the primary lesion or a metastatic lesion). - Has provided prior to allocation tissue from a newly obtained formalin-fixed sample from a new biopsy (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and before receiving a randomization number), of a tumor lesion not previously irradiated. - Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention but before randomization. - Has a life expectancy of at least 3 months. - Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) follow contraceptive guidance during the treatment period or 7 days after the last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the same conditions during the treatment period and for =90 days after the last dose of study treatment. - Female participants must not be pregnant, not be breastfeeding, and not be a woman of child-bearing potential (WOCBP). If a WOCBP, agrees to not donate eggs and either use contraception, or be abstinent from heterosexual intercourse during the treatment period and for =120 days after the last dose of pembrolizumab or 30 days after the last dose of lenvatinib, whichever occurs last. If a WOCBP receiving docetaxel, agrees to adhere to the same conditions during the treatment period and for =30 days after the last dose of study treatment. - Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP =150/90 mm Hg and no change in antihypertensive medications within 1 week before randomization. - If participant received major surgery or radiation therapy of >30 Gy, they have recovered from the toxicity and/or complications from the intervention. - Has adequate organ function. Exclusion Criteria: - Has received docetaxel as monotherapy or in combination with other therapies. - Has received lenvatinib as monotherapy or in combination with an anti-PD-1/PD-L1 mAb. - Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment; or 2) lung radiation therapy >30 Gy within 6 months before the first dose of study treatment. - Has received a live vaccine within 30 days before the first dose of study treatment. - Has clinically significant hemoptysis or tumor bleeding within 2 weeks before the first dose of study treatment. - Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a major blood vessel. - Has clinically significant cardiovascular impairment within 12 months of the first dose of study treatment. - Has a history of a gastrointestinal condition or procedure that may affect oral absorption of study treatment. - Has a pre-existing =Grade 3 gastrointestinal or non-gastrointestinal fistula. - Is currently participating in a clinical trial and receiving study therapy or participated in a study of an investigational agent within 4 weeks of the first dose of study treatment. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study treatment. - Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy. - Has known active central nervous system metastases and/or carcinomatous meningitis. - Has severe hypersensitivity to pembrolizumab and/or any of its excipients. - Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel. - Has an active autoimmune disease that has required systemic treatment in the past 2 years. - Has a history of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease. - Has an active infection requiring systemic therapy. - Has a known history of human immunodeficiency virus (HIV) infection. - Has a known history of hepatitis B reactive or known active hepatitis C virus infection. - Has active tuberculosis. - Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study. - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through at least 120 days after the last dose of pembrolizumab or lenvatinib, or 90 days (male participants) or 30 days (for female participants) after the last dose of docetaxel. - Has had an allogeneic tissue/solid organ transplant.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Pembrolizumab
IV infusion of pembrolizumab at 200 mg
Drug:
Lenvatinib
Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
Docetaxel
IV infusion of docetaxel at 75 mg/m^2.

Locations

Country Name City State
Argentina CEMIC ( Site 2003) Buenos Aires
Argentina Hospital Aleman ( Site 2000) Buenos Aires
Argentina Hospital Britanico de Buenos Aires ( Site 2002) Buenos Aires Caba
Argentina Instituto de Investigaciones Metabolicas ( Site 2004) Caba Buenos Aires
Argentina Sanatorio Parque ( Site 2005) Rosario Santa Fe
Australia Bendigo Cancer Centre ( Site 0008) Bendigo Victoria
Australia Blacktown Hospital ( Site 0004) Blacktown New South Wales
Australia Calvary Central Districts Hospital ( Site 0007) Elizabeth Vale South Australia
Australia Port Macquarie Base Hospital ( Site 0003) Port Macquarie New South Wales
Australia Westmead Hospital ( Site 0005) Westmead New South Wales
Australia Southern Medical Day Care Centre ( Site 0001) Wollongong New South Wales
Australia Princess Alexandra Hospital - Division of Cancer Services ( Site 0002) Woolloongabba Queensland
Canada Kingston Health Sciences Centre ( Site 1503) Kingston Ontario
Canada London Regional Cancer Program - London HSC ( Site 1505) London Ontario
Canada CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 1501) Montreal Quebec
Canada CHUQ-Univ Laval-Hotel Dieu de Quebec ( Site 1514) Quebec
Canada Princess Margaret Cancer Centre ( Site 1502) Toronto Ontario
Canada CancerCare Manitoba ( Site 1504) Winnipeg Manitoba
Colombia Clinica de la Costa Ltda. ( Site 1309) Barranquilla Atlantico
Colombia Administradora Country SA - Clinica del Country ( Site 1307) Bogota Distrito Capital De Bogota
Colombia Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1304) Bogota Distrito Capital De Bogota
Colombia Centro Medico Imbanaco de Cali S.A ( Site 1301) Cali Valle Del Cauca
Colombia Rodrigo Botero SAS ( Site 1300) Medellin Antioquia
Colombia Oncomedica S.A. ( Site 1302) Monteria Cordoba
Colombia Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1305) Valledupar Cesar
France ICO Centre Paul Papin ( Site 0412) Angers Maine-et-Loire
France Centre Hospitalier General - Avignon ( Site 0407) Avignon Provence-Alpes-Cote-d Azur
France Clinique Ambroise Pare ( Site 0402) Beuvry Pas-de-Calais
France CHU Caen Service de Pneumologie ( Site 0401) Caen Calvados
France HIA Percy-Clamart ( Site 0411) Clamart Hauts-de-Seine
France Centre Hospitalier Le Mans ( Site 0406) Le Mans Sarthe
France Hopital Europeen Georges Pompidou ( Site 0408) Paris
France Institut Curie ( Site 0400) Paris
Germany Vivantes Klinikum Spandau ( Site 0505) Berlin
Germany SRH Wald-Klinikum Gera GmbH ( Site 0503) Gera Thuringen
Germany Evangelisches Krankenhaus Hamm gGmbH ( Site 0504) Hamm Nordrhein-Westfalen
Germany Thoraxklinik Heidelberg gGmbH am Universitaetsklinikum Heidelberg ( Site 0501) Heidelberg Baden-Wurttemberg
Greece General Hospital of Chest Diseases "Sotiria" ( Site 1703) Athens Attiki
Greece Metropolitan Hospital-4th Oncology Dept ( Site 1700) Athens Attiki
Greece University Hospital of Ioannina ( Site 1701) Ioannina
Greece European Interbalkan Medical Center ( Site 1704) Thessaloniki
Hungary Orszagos Koranyi Pulmonologiai Intezet ( Site 0603) Budapest
Hungary Orszagos Koranyi Pulmonologiai Intezet ( Site 0608) Budapest
Hungary Semmelweis Egyetem.. ( Site 0604) Budapest
Hungary Veszprem Megyei Tudogyogyintezet ( Site 0607) Farkasgyepu Veszprem
Hungary Petz Aladar Megyei Oktato Korhaz ( Site 0609) Gyor Gyor-Moson-Sopron
Hungary Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház ( Site 0601) Miskolc Borsod-Abauj-Zemplen
Hungary Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 0606) Szekesfehervar Fejer
Hungary Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0610) Szolnok Jasz-Nagykun-Szolnok
Hungary Tudogyogyintezet Torokbalint ( Site 0602) Torokbalint Pest
Israel Soroka Medical Center ( Site 0701) Beer Sheva
Israel Rambam Medical Center ( Site 0703) Haifa
Israel Shaare Zedek Medical Center-Oncology ( Site 0706) Jerusalem
Israel Meir Medical Center ( Site 0702) Kfar-Saba
Israel Rabin Medical Center ( Site 0700) Petah Tikva
Israel Chaim Sheba Medical Center ( Site 0704) Ramat Gan
Israel Sourasky Medical Center (Ichilov) - Oncology Clinic ( Site 0705) Tel Aviv
Italy Azienda Ospedaliera San Giuseppe Moscati ( Site 0809) Avellino
Italy IRCCS Giovanni Paolo II. Ospedale Oncologico ( Site 0808) Bari
Italy AOU Policlinico Vittorio Emanuele ( Site 0811) Catania
Italy Istituto Nazionale dei Tumori ( Site 0806) Milano
Italy Ospedale San Gerardo - ASST Monza ( Site 0804) Monza Monza E Brianza
Italy Ospedale San Luigi Gonzaga ( Site 0802) Orbassano Torino
Italy A.O. Ospedali Riuniti Villa Sofia - Cervello P.O. Villa Sofia ( Site 0810) Palermo Sicilia
Italy Policlinico San Matteo - Fondazione IRCCS ( Site 0812) Pavia
Italy Azienda Ospedaliera di Perugia ( Site 0805) Perugia
Italy Istittuto Nazionale dei Tumori Regina Elena IRCCS - IFO ( Site 0807) Rome Roma
Japan Chiba University Hospital ( Site 0106) Chiba
Japan Kansai Medical University Hospital ( Site 0104) Hirakata Osaka
Japan Niigata Cancer Center Hospital ( Site 0101) Niigata
Japan Sendai Kousei Hospital ( Site 0107) Sendai Miyagi
Japan National Cancer Center Hospital ( Site 0103) Tokyo
Japan The Cancer Institute Hospital of JFCR ( Site 0100) Tokyo
Japan Kanagawa Cardiovascular and Respiratory Center ( Site 0105) Yokohama Kanagawa
Korea, Republic of Chungbuk National University Hospital ( Site 0201) Cheongju si Chungbuk
Korea, Republic of Seoul National University Bundang Hospital ( Site 0204) Seongnam-si Kyonggi-do
Korea, Republic of Severance Hospital Yonsei University Health System ( Site 0202) Seoul
Korea, Republic of Asan Medical Center ( Site 0203) Songpagu Seoul
Portugal Centro Hospitalar Lisboa Norte E.P.E. - Hospital Pulido Valente ( Site 1801) Lisboa
Portugal Hospital CUF Porto ( Site 1802) Porto
Portugal Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 1800) Porto
Puerto Rico Hematology and Oncology Institute ( Site 2105) Manati
Puerto Rico Ad-Vance Medical Research LLC ( Site 2103) Ponce
Puerto Rico Puerto Rico Medical Research Center LLC ( Site 2101) San Juan
Russian Federation Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 0918) Krasnoyarsk Krasnoyarskiy Kray
Russian Federation Central Clinical Hospital of the Administration of the President ( Site 0910) Moscow Moskva
Russian Federation Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0905) Moscow Moskva
Russian Federation Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site Omsk Omskaya Oblast
Russian Federation SPb SBHI City Clinical Oncological Dispensary ( Site 0901) Saint Petersburg Sankt-Peterburg
Russian Federation Railway Hospital of OJSC ( Site 0907) Saint-Petersburg Sankt-Peterburg
Russian Federation Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0903) Saint-Petersburg Sankt-Peterburg
Russian Federation GBUZ SPb CRPCstmc(o) ( Site 0921) Sankt- Peterburg Sankt-Peterburg
Russian Federation Pavlov First Saint Petersburg State Medical University ( Site 0917) St. Petersburg Sankt-Peterburg
Russian Federation GBUZ Republican Clinical Oncological Dispensary ( Site 0922) Ufa Baskortostan, Respublika
Spain Hospital Universitari Vall d Hebron ( Site 1004) Barcelona
Spain Hospital Ciudad de Jaen ( Site 1000) Jaen
Spain Hospital Universitario Insular de Gran Canaria ( Site 1011) Las Palmas de Gran Canaria Las Palmas
Spain Hospital Universitario 12 de Octubre ( Site 1006) Madrid
Spain Hospital Universitario Fundacion Jimenez Diaz ( Site 1005) Madrid
Spain Hospital Universitario Puerta de Hierro ( Site 1007) Majadahonda Madrid
Spain Consorci Hospitalari Mataro ( Site 1008) Mataro Barcelona
Spain Hospital Central de Asturias ( Site 1002) Oviedo Asturias
Spain Hospital Universitario Quiron Madrid ( Site 1012) Pozuelo de Alarcon Madrid
Spain Hospital Universitario Marques de Valdecilla ( Site 1003) Santander Cantabria
Spain Hospital Clinico de Valencia ( Site 1010) Valencia Valenciana, Comunitat
United Kingdom Aberdeen Royal Infirmary ( Site 1114) Aberdeen Scotland
United Kingdom Birmingham Heartlands Hospital ( Site 1103) Birmingham
United Kingdom Hull & East Yorkshire NHS Trust. Castle Hill Hospital ( Site 1108) Cottingham East Riding Of Yorkshire
United Kingdom University Hospital Coventry and Warwickshire NHS Trust ( Site 1112) Coventry Warwickshire
United Kingdom St James s University Hospital ( Site 1106) Leeds
United Kingdom Leicester Royal Infirmary ( Site 1110) Leicester Leicestershire
United Kingdom Guy s and St Thomas Hospital NHS Foundation Trust ( Site 1102) London London, City Of
United Kingdom North Middlesex University Hospital NHS Trust ( Site 1109) London London, City Of
United Kingdom Mount Vernon Cancer Centre ( Site 1107) Northwood London, City Of
United Kingdom Nottingham City Hospital Campus ( Site 1105) Nottingham England
United States Comprehensive Blood & Cancer Center [Bakersfield, CA] ( Site 1604) Bakersfield California
United States Harry & Jeanette Weinberg Cancer Institute ( Site 1626) Baltimore Maryland
United States Medstar Good Samaritan Hospital ( Site 1625) Baltimore Maryland
United States Memorial Sloan-Kettering Cancer Center At Basking Ridge ( Site 1664) Basking Ridge New Jersey
United States Hematology Oncology Clinic ( Site 1680) Baton Rouge Louisiana
United States Billings Clinic ( Site 1631) Billings Montana
United States Massachusetts General Hospital ( Site 1622) Boston Massachusetts
United States Bozeman Health Deaconness Cancer Center ( Site 1632) Bozeman Montana
United States TriHealth Cancer Institute ( Site 1672) Cincinnati Ohio
United States MetroHealth Medical Center ( Site 1694) Cleveland Ohio
United States Memorial Sloan-Kettering Cancer Center at Commack ( Site 1662) Commack New York
United States MGH - North Shore Cancer Center ( Site 1668) Danvers Massachusetts
United States Cancer Specialists of North Florida - Fleming Island ( Site 1675) Fleming Island Florida
United States Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 1666) Harrison New York
United States Millenium Physicians ( Site 1690) Houston Texas
United States Thompson Cancer Survival Center ( Site 1695) Knoxville Tennessee
United States University of Kentucky School of Medicine & Hospitals ( Site 1621) Lexington Kentucky
United States Memorial Sloan-Kettering Cancer Center at Middletown ( Site 1665) Middletown New Jersey
United States Memorial Sloan-Kettering Cancer Center at Montvale ( Site 1667) Montvale New Jersey
United States Memorial Sloan-Kettering Cancer Center ( Site 1661) New York New York
United States The Mass General Cancer Center at Newton-Wellesley ( Site 1692) Newton Massachusetts
United States Mid-Florida Cancer Centers ( Site 1611) Orange City Florida
United States Fox Chase Cancer Center ( Site 1647) Philadelphia Pennsylvania
United States New York Cancer and Blood Specialists ( Site 1696) Port Jefferson Station New York
United States Kaiser Permanente Center for Health Research-Kaiser Permanente Medical Center ( Site 1644) Portland Oregon
United States University of Rochester ( Site 1638) Rochester New York
United States Memorial Sloan Kettering Cancer Center - Nassau ( Site 1670) Uniondale New York
United States University of Massachusetts Medical School ( Site 1693) Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC Eisai Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Canada,  Colombia,  France,  Germany,  Greece,  Hungary,  Israel,  Italy,  Japan,  Korea, Republic of,  Portugal,  Puerto Rico,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival (OS) OS is defined as the time from randomization to the date of death due to any cause. Up to ~48 months
Primary Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS will be assessed by blinded independent central review (BICR) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Up to ~36 months
Secondary Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Up to ~18 months
Secondary Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Up to ~36 months
Secondary Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) DOR is defined as the time from first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) until disease progression or death due to any cause, whichever occurs first. DOR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Up to ~48 months
Secondary Number of Participants Experiencing an Adverse Event (AE) An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented. Up to ~79 months
Secondary Number of Participants Discontinuing Study Treatment Due to an AE The number of participants who discontinue study treatment due to an AE will be presented. Up to ~79 months
Secondary Change from Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of cancer patients, including a combined global health status (GHS)/QoL (Items 29 and 30) scale. For each item, scores range from 0-100, with higher scores indicating higher GHS/QoL. Per protocol, scores for items 29 and 30 will be averaged to compute a combined GHS/QoL scale score. Change from baseline in the combined GHS/QoL scale score will be presented. Baseline and Week 12
Secondary Change from Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). For this item, individual responses to the question "How much did you cough?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough (Item 31) scale score will be presented. Baseline and Week 12
Secondary Change from Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). For this item, individual responses to the question "Have you had pain in your chest?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented. Baseline and Week 12
Secondary Change from Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). For this item, individual responses to the question "Were you short of breath?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea (Item 8) scale score will be presented. Baseline and Week 12
Secondary Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The PF scale consists of participant responses to 5 questions regarding performance of daily activities [1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet]. Overall PF scores range from 0 to 100, with a lower score indicating a better outcome. The change from Baseline in the EORTC QLQ-C30 PF (Items 1 to 5) scale combined score will be presented. Baseline and Week 12
Secondary Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. The TTD in the combined GHS/QoL (Items 29 & 30) scale combined score will be presented, defined as the time to first onset of a =10 point decrease from baseline. Up to ~48 months
Secondary Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). The TTD in EORTC QLQ-LC13 cough (Item 31) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline. Up to ~48 months
Secondary Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). The TTD in EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline. Up to ~48 months
Secondary Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). The TTD in dyspnea (Item 8) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline. Up to ~48 months
Secondary Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The TTD in PF (Items 1 to 5) scale combined score will be presented, defined as the time to first onset of a =10 point decrease from baseline. Up to ~48 months
See also
  Status Clinical Trial Phase
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Not yet recruiting NCT05985330 - Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
Recruiting NCT05013450 - Dupilumab_Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT05984277 - A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. Phase 3
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Completed NCT05675683 - Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
Active, not recruiting NCT02411448 - A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) Phase 3
Recruiting NCT04410796 - Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers Phase 2
Recruiting NCT06343402 - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer Phase 1
Recruiting NCT03300115 - Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC Phase 2
Recruiting NCT05635708 - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer Phase 2
Terminated NCT03265080 - A Study of ADXS-NEO Expressing Personalized Tumor Antigens Phase 1
Active, not recruiting NCT05226598 - Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Phase 3
Withdrawn NCT02639234 - Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer Phase 2
Recruiting NCT05364073 - Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations Phase 1
Completed NCT03926260 - Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA N/A
Recruiting NCT05546905 - A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Not yet recruiting NCT06428422 - The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients N/A
Active, not recruiting NCT06212752 - A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension Phase 3